Announcement • Jun 23
BetterLife Pharma Inc. announced that it has received CAD 2 million in funding On June 22, 2026, BetterLife Pharma Inc. has closed the transaction. Announcement • Jun 16
BetterLife Pharma Inc. announced that it expects to receive CAD 2 million in funding BetterLife Pharma Inc. has announced a non-brokered private placement of 10% convertible debenture of the company to raise gross proceeds of CAD 2,000,000 on June 15, 2026. The debenture are 100% convertible into common units of the company at a conversion price value of CAD 0.06 per unit and carry interest rate of 10% and with each unit comprising of one common share and one share purchase warrant exercisable at CAD 0.10 for three years from issuance. All securities issued in connection with the Financing will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. A director and insider of the company intends to participate in the financing by subscribing for CAD 2,000,000 of the Debenture. The bonds will mature one year from closing. The transaction is expected to close on June 25, 2026. Recent Insider Transactions • May 26
Board Member recently sold CA$253k worth of stock On the 25th of May, Stephen Sangha sold around 4m shares on-market at roughly CA$0.06 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought CA$246k more than they sold in the last 12 months. Announcement • Apr 18
BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in funding On April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering. Announcement • Apr 09
BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding BetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. Board Change • Jan 13
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Founder, CEO & Chairman Ahmad Doroudian is the most experienced director on the board, commencing their role in 2020. Independent Director Tony Pullen was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. New Risk • Dec 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$218k free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-CA$6.2m). Revenue is less than US$1m. Market cap is less than US$10m (CA$7.82m market cap, or US$5.71m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). New Risk • Aug 12
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.7m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.2m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$6.1m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.7m market cap, or US$9.97m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). Board Change • Aug 11
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Tony Pullen was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • May 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.0m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$7.4m). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (CA$15.3m market cap, or US$11.1m). Announcement • May 28
Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001 BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026. New Risk • May 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$6.6m). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (CA$16.2m market cap, or US$11.8m). Announcement • May 19
BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025 BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025. Announcement • May 15
BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases. Announcement • Mar 31
BetterLife Pharma Inc. Appoints Steven Sangha to its Board of Directors BetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia. Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board John McCorvy was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. New Risk • Dec 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$2.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$2.3m free cash flow). Negative equity (-CA$6.6m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.8m market cap, or US$9.60m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Announcement • Nov 27
BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001 BetterLife Pharma Inc. announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether- a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning. Announcement • Oct 23
BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001 BetterLife Pharma Inc. announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities. The GLP genotoxicity studies conducted on BETR-001 included in vitro bacterial reverse mutation assay, in vitro micronucleus test, and in vivo micronucleus test in male and female rats. These studies are a critical component of the safety assessment required by the U.S. Food and Drug Administration (FDA) and needed for entry into clinical trials. New Risk • Oct 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.4m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-CA$7.6m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.4m market cap, or US$9.74m). Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding). Announcement • Aug 29
BetterLife Pharma Inc. announced that it expects to receive CAD 1.1 million in funding BetterLife Pharma Inc announced a non brokered private placement offering of 7,333,333 units issued at a price of CAD 0.15 per unit for gross proceeds CAD 1,099,999.95 on August 29, 2024. Each unit consisting of one common share in the capital of the Company and one full common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD 0.20 for up to two years following the date of the closing of the Private Placement. The close is subject to the receipt of all necessary regulatory and other approvals which will be announced as soon as it has been completed. New Risk • Aug 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.3m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-CA$7.8m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.3m market cap, or US$9.78m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Announcement • Jul 03
BetterLife Pharma Inc. announced that it has received CAD 0.175 million in funding On July 2, 2024, BetterLife Pharma Inc. closed the transaction. Announcement • May 15
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 BetterLife Pharma Inc. announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials did not show any significant cardiopulmonary pharmacological safety issues in animals. Cardiopulmonary safety (also known as telemetry) studies investigate the effect of a drug in animals using surgically implanted transmitters to assess blood pressure, electrocardiography (ECG), lung respiration, body temperature, and general activity level. The BETR-001 cardiopulmonary study found no BETR-001 related effects on ECG intervals, respiratory parameters, core body temperature, or activity levels. Announcement • May 03
BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies BetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024. Announcement • Apr 13
BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024 BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024. Announcement • Apr 04
BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding BetterLife Pharma Inc. announced a private placement for issuance of 10% convertible debentures for gross proceeds of CAD 1,168,000 on April 3, 2024. The CAD 800,000 of the convertible debentures matures on March 27, 2026 and CAD 368,000 mature on April 1, 2026. The convertible debentures are convertible at the option of the holder into units, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on either September 27, 2026 or October 1, 2026. The transaction included participation from returning investors Ahmad Doroudian, Chief Executive Officer of the company, and Steven Sangha for CAD 100,000 each. Announcement • Mar 05
BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding BetterLife Pharma Inc. announced a private placement to issue convertible debentures for the gross proceeds of CAD 100,000 on March 4, 2024. The transaction will include participation from individual investor such as Ahmad Doroudian for CAD 100,000. Announcement • Mar 04
BetterLife Pharma Inc. announced that it has received CAD 0.065 million in funding BetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026. The debentures bear 10% interest rate and matures on February 28, 2026. Announcement • Jan 02
BetterLife Pharma Inc. announced that it has received CAD 0.3 million in funding BetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering. Announcement • Dec 18
BetterLife Pharma Inc. announced that it has received CAD 0.2 million in funding BetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 2,000,000 units at an issue price of CAD 0.10 per Unit for aggregate gross proceeds of CAD 200,000 on December 18, 2023. Each Unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.10 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of 1,000,000 Units under the Offering. Announcement • Dec 01
Us Patent and Trademark Office Publishes Betterlife’S Comprehensive Patent for Betr-001 and Other Lsd Derivatives BetterLife Pharma Inc. announced that its patent application for BETR-001 and LSD derivatives titled “LSD derivatives, synthesis & method for treatment of diseases and disorders” has been published by the United States Patent and Trademark Office under publication number US-2023/0357243-A1 and available for access on USPTO’s databases. BetterLife is presently developing one of these derivatives: a 2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic and, in preclinical animal models, has been shown to be a potent neuroplastogen and have efficacy against depression/anxiety states. This published U.S. patent is part of a developing international patent portfolio which cover new compositions of 2-bromo-LSD and other LSD derivatives. In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of controlled substances at any stage. The applications also cover use of these derivatives in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and neuropathic pain. Betterlife is also pleased that its efforts to develop novel therapies for mental disorders were highlighted in the November 8 edition of The Atlantic. The Atlantic journal highlighted the potential of the BETR-001 program, as a non-hallucinogenic analog of LSD, in an article entitled “What If Psychedelics’ Hallucinations Are Just a Side Effect?” The article discusses, in part, that a growing number of key opinion leaders in neuroscience now believe that the hallucination caused by psychedelics is just a side effect and not necessary to produce mental-health benefits by this class of drugs. BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024. Announcement • Jul 14
BetterLife Pharma Inc. announced that it has received CAD 0.22 million in funding BetterLife Pharma Inc. announced a non-brokered private placement of 2,200,000 units at a price of CAD 0.10 per non-brokered unit for aggregate gross proceeds of CAD 220,000 on July 13, 2023. Each non-brokered unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.15 at any time up of 60 months from the closing of the offering. The units sold pursuant to the offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. Announcement • Jun 23
BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development Advisor BetterLife Pharma Inc. announced the appointment of Dr. Steven Sangha as corporate development advisor to the Company. Dr. Sangha has over 25 years of experience in investment banking, business development and asset management. His extensive experience with public company governance and compliance, and finance has led him to successfully run a Private Fund Family Office. Dr. Sangha’s interest in the biotechnology industry has allowed positive growth for early-stage companies with his consummate efforts in assessment, development and financial support. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia. Announcement • Jun 09
BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling Studies BetterLife Pharma Inc. announced that the IND-enabling studies BetterLife's 2-bromo-LSD ("BETR -001") continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide ("LSD") derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/an anxiety animal models without hallucinogenic activity. The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion. The in-life portion of the 28-day repeat dose GLP toxicology study in dogs has now been completed, and the histopathological analyses are ongoing. The GMP manufacturing of BETR-001 drug substance is also in its final stages. Recent Insider Transactions • Apr 23
Founder recently bought CA$69k worth of stock On the 14th of April, Ahmad Doroudian bought around 659k shares on-market at roughly CA$0.10 per share. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Ahmad has been a buyer over the last 12 months, purchasing a net total of CA$121k worth in shares. Recent Insider Transactions • Feb 19
Founder recently bought CA$53k worth of stock On the 14th of February, Ahmad Doroudian bought around 330k shares on-market at roughly CA$0.16 per share. This transaction amounted to 6.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ahmad's only on-market trade for the last 12 months. Announcement • Jan 17
BetterLife Pharma Inc., Annual General Meeting, Mar 30, 2023 BetterLife Pharma Inc., Annual General Meeting, Mar 30, 2023. Announcement • Dec 08
BetterLife Pharma Inc. announced that it has received $0.474 million in funding from Negev Capital and other investors BetterLife Pharma Inc. announced a non brokered private placement of 3,160,000 common shares at a price of $0.15 per common share for gross proceeds of $474,000 on December 7, 2022. The transaction included participation from new investors, Negev Capital and certain European-based investors The securities issued in the transaction will be subject to resale restrictions for a period of four months and one day from the date of issuance. Board Change • Nov 16
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. Independent Director Wolfgang Renz is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Sep 29
BetterLife Pharma Inc. Files Comprehensive Patent for BETR-001 and Other LSD Derivatives BetterLife Pharma Inc. announced filing of a PCT patent application along with a U.S. application for lysergic acid diethylamide ("LSD") derivatives, including 2-bromo-LSD. The applications cover compositions of these derivatives for their use in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and pain. The company is currently developing a new composition of 2-bromo-LSD ("BETR-001") covered by these patent filings. BETR-001 is a second-generation LSD derivative molecule that does not cause hallucinations, and therefore is not subject to global controlled substance regulations. In addition, the synthesis of BETR-001 is via non-controlled substance synthetic routes, and therefore not subject to controlled substance regulatory restrictions. The company is already in advanced stages of GMP manufacturing of BETR-001 and completing the necessary preclinical IND-enabling studies for BETR-001. The company expects to file the BETR-001 IND and start Phase 1, in healthy subjects, in first half of 2023. Board Change • Sep 01
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. No highly experienced directors. Independent Director Wolfgang Renz is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Jul 07
BetterLife Pharma Inc. Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies BetterLife Pharma Inc. announced that a joint application to the Mitacs Accelerate program, in collaboration with Dr. Argel Aguilar-Valles at Carleton University (Carleton) Department of Neuroscience, was successfully funded for research into the anti-depressant effects and mechanism of action ("MOA") of BETR-001 in preclinical models of depression. BETR-001 is a second-generation Lysergic Acid Diethylamide ("LSD") derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations. Announcement • Jun 02
BetterLife Pharma Inc. announced delayed 20-F filing On 06/01/2022, BetterLife Pharma Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Board Change • Apr 27
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. No highly experienced directors. Independent Director Wolfgang Renz is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 07
BetterLife Pharma Inc. Obtains Additional Positive Data Confirming the Anti-Depressant Activity of Its Lead Compound 2-bromo-LSD (BETR-001) in Preclinical Models of Depression BetterLife Pharma Inc. announce it has obtained additional positive data confirming the anti-depressant activity of its lead compound 2-bromo-LSD ("BETR-001") in preclinical models of depression. The study is part of BetterLife's collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University's (Carleton) Department of Neuroscience. BETR-001 is a second-generation Lysergic Acid Diethylamide ("LSD") derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations. The current study evaluated the anti-depressant activity of BETR-001 on depressive-like behavior of mice in a forced swim test. The amount of time mice spend immobile (a depression-like behavior) was significantly reduced 24 hours after treatment with single dose of BETR-001 (1.0 mg/kg) compared to the untreated control group. BETR-001 had no effect on the locomotion behavior of mice in this study, suggesting the increased mobility in the forced swim test was due to its anti-depressant activity. Announcement • Feb 16
Betterlife Pharma Inc. Lead Drug Promotes Structural Neural Plasticity in Preclinical Model BetterLife Pharma Inc. announced it has obtained positive results from a preclinical neural plasticity study of BETR-001 in cortical rat neurons, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University's (Carleton) Department of Neuroscience. BETR-001 (2-bromo-LSD, formerly TD-0148A) is a non-hallucinogenic derivative of lysergic acid diethylamide (LSD). Atrophy of neurons in the brain plays a critical role in pathophysiology of depression and related disorders. Increased structural plasticity in the brain neurons (mainly prefrontal cortex) has been linked to the sustained antidepressant effects of ketamine and other psychedelic compounds. BetterLife had previously shown the anti-depressant properties of BETR-001 in a rodent chronic variable stress model. The current study demonstrates that treatment of rat embryonic cortical neurons with BETR-001 increases the structural complexity of neurons (dendrite growth and complexity) and therefore, provides evidence of neural plasticity activity of BETR-001. In certain measurements of structural plasticity in neurons, BETR-001 performs better than ketamine in this model. Announcement • Jan 22
BetterLife Pharma Inc. Receives FDA Response on its Pre-IND Application for Major Depressive Disorder Treatment with BETR-001 BetterLife Pharma Inc. announced it has received a written response from the U.S. Food and Drug Administration to its pre-investigational new drug (pre-IND) application for the treatment of MDD with BETR-001. BETR-001 (2-bromo-LSD, formerly TD-0148A) is a non-hallucinogenic derivative of lysergic acid diethylamide (LSD) and is currently undergoing IND-enabling non-clinical studies and GMP manufacturing for clinical trials. The FDA response is in general agreement with the Company’s planned program for the development of BETR-001 and provided guidance regarding the BETR-001 IND-enabling non-clinical toxicology studies, its manufacturing strategy, and initial proposed clinical trial parameters. Announcement • Jan 19
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001 BetterLife Pharma Inc. announced it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK) study on BETR-001 in beagle dogs. BETR-001 (2-bromo-LSD, formerly TD-0148A) is a non-hallucinogenic derivative of lysergic acid diethylamide (LSD). Previous published studies have not included any data on PK for BETR-001. It was also unknown if presence of food would affect the bioavailability of orally administered BETR-001. The current study conducted by contract research organization, Nucro-Technics (Scarborough, ON, Canada), demonstrated the following key results after a single dose of oral BETR-001 (capsule) administered to beagle dogs:No significant difference was observed in bioavailability and total exposure of BETR-001 in PK profile of fed versus fasted beagle dogs;Oral bioavailability (%F), defined as the fraction of oral administered drug that reaches systemic circulation, was calculated to be 61% and 63% for fasted and fed states, respectively (no significant difference); The maximum systemic concentration (Cmax) of BETR-001 after a single oral dose was reached at 0.5 hr (Tmax), suggesting a quick uptake of the drug into the systemic circulation. The drug was detectable in systemic circulation eight hours post oral dose with an elimination rate constant (Kel) of 0.4 per hour, pointing to the fraction of drug eliminated per unit of time. The findings demonstrate that oral administration of a single dose of BETR-001 can reach the therapeutic range in the systemic circulation. The PK elimination constant (Kel) of 0.4 per hour for BETR-001 indicates a low probability of toxicity as a result of drug accumulation in the systemic circulation. Announcement • Dec 24
An unknown buyer agreed to acquire BetterLife Europe Pharmaceuticals AG from BetterLife Pharma Inc. for €0.17 million. An unknown buyer agreed to acquire BetterLife Europe Pharmaceuticals AG from BetterLife Pharma Inc. for €0.17 million on December 16, 2021. Announcement • Dec 11
BetterLife Pharma Inc. Obtains Positive TD-0148A Data in Preclinical Models of Depression BetterLife Pharma Inc. announced it has obtained the first set of positive data showing anti-depressant properties of its lead compound, 2-bromo-LSD in animal depression models, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University’s (Carleton) Department of Neuroscience. TD-0148A is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations. Both single and repeat dose treatments with TD-0148A significantly reversed the depressive-like behavior in chronically-stressed female mice. The depressive-like behaviors assessed in the study included open-field test (a measure of exploratory behavior) and splash test (measure of anhedonia and self-hygiene behavior). Female mice demonstrated clear signs of depression following CVS as indicated by significant reduction in exploratory and grooming behaviors in open-field and splash tests, respectively. However, TD-0148A treatment showed anti-depressant activity by significantly reversing both depressive-like behaviors in these mice. Recent Insider Transactions • Dec 10
Founder recently bought CA$91k worth of stock On the 7th of December, Ahmad Doroudian bought around 326k shares on-market at roughly CA$0.28 per share. This was the largest purchase by an insider in the last 3 months. This was Ahmad's only on-market trade for the last 12 months. Announcement • Sep 29
Betterlife Pharma Inc. Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders BetterLife Pharma Inc. applied for patent protection of new compositions of 2-bromo-LSD for its use in the treatment of cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders. BetterLife is developing one of the new compositions of 2-bromo-LSD covered by its newly filed provisional patent application. TD-0148A is a second-generation lysergic acid diethylamide derivative molecule that does not cause hallucinations, and therefore not subject to controlled substance regulations. In addition, the synthesis of TD-1048A is via non-controlled substance synthetic routes and therefore not subject to controlled substance regulatory restrictions. BetterLife is already in advanced stages of GMP manufacturing TD-0148A and initiated the necessary preclinical IND-enabling studies for TD-0148A. TD-0148A is currently in preclinical pharmacology and other IND-enabling studies and in 2022, BetterLife will file its IND and start Phases 1 and 2 in healthy subjects for major depressive disorder. Announcement • Sep 24
BetterLife Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile BetterLife Pharma Inc. announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. ("Altum"), and Pontificia Universidad Católica de Chile have enrolled the first patient in the Phase 1 portion of the Phase 1-2 randomized placebo controlled ("IN2COVID") in COVID-19 patients. The trial tests BetterLife's proprietary inhaled interferon alpha-2b product, AP-003. The IN2COVID trial (ClinicalTrials.gov Identifier: NCT04988217) consists of a randomized placebo Phase 1 portion in healthy subjects followed by a randomized placebo-controlled Phase 2 portion in early stage COVID-19 patients (<5 days of diagnosis of COVID-19). The IFN-2b treatment arms will receive BetterLife's proprietary inhaled IFN-2b product, AP-003, administered via nebulizer, twice daily for 10 days. Dr. Eleanor Fish, one of the Principal Investigators of the trial, commented, "AP-003, being a Type I interferon, is a broad acting antiviral agent and, therefore, may be effective in all the scenarios described by my colleague Dr. Borzutzky." Dr. Fish is a Professor in the Department of Immunology, University of Toronto, and Emerita Scientist at the Toronto General Hospital Research Institute, University Health Network. Dr. Fish is the principal author of the exploratory trial published in 2020 in Frontiers of Immunology titled "Interferon-2b Treatment for COVID-19", which examined the outcome of treating a cohort of 77 individuals with confirmed COVID-19 admitted to Union Hospital, Wuhan, China, with inhaled interferon-2b. The study revealed the therapeutic benefits of Interferon-2b treatment in patients with early COVID-19. The authors concluded that a
randomized clinical trial was warranted in moderate cases of COVID-19 and "treatment with IFN-2 may benefit public health measures aimed at slowing the tide of this pandemic, in that this exploratory study demonstrated that duration of viral shedding was shortened, and lung abnormalities and systemic inflammation were significantly reduced." The current IN2COVID trial in Chile was designed to test these. Announcement • Aug 26
BetterLife Pharma Inc. Initiates Preclinical Study of Ap-003 (Rhifna2b) Against Delta Variant of Sars-Cov-2 BetterLife Pharma Inc. announced initiation of in vitro studies of its recombinant human interferon alpha-2b ("rhIFN2b" or "AP-003") against the Delta variant of SARS-CoV-2. The studies are being conducted at Dr. Stephen Barr's Laboratory at the ImPaKT Facility at Western University ("UWO"). AP-003's first proposed target indication is for people at higher risk to develop severe COVID-19 disease. These in-vitro anti-viral studies of AP-003 against the Delta variant are a follow on to earlier in-vitro studies conducted at UWO which have shown potent and similar anti-viral activity of AP-003 against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants. The Company expects to release the results on the of rhIFN2b /AP-003 activity against Delta variant in the next two weeks. Announcement • Jul 16
Betterlife Pharma Inc. Announces Early Positive in Vitro Results of Its Sars-Cov-2 (“Covid-19”) Anti-Viral, Recombinant Human Interferon Alpha-2B BetterLife Pharma Inc. announced early positive in vitro results of its SARS-CoV-2 (“COVID-19”) anti-viral, recombinant human interferon alpha-2b, from the Dr. Stephen Barr Laboratory and ImPaKT Facility at Western University (“UWO”). AP-003’s first proposed target indication is for people at higher risk to develop severe COVID-19 disease. Early data show potent and similar anti-viral activity against the COVID-19 Wuhan reference strain (EC50=0.51), Alpha (B.1.1.7, UK, EC50=1.26) and Beta (B.1.351, South Africa, EC50=0.25) variants. Further studies are ongoing to validate these early results and to test AP-003 activity against Gamma (Brazil), Delta (India) and Lambda (Peru) variants. The rhIFN?2b, a Type I interferon, is a naturally occurring protein integral to the body’s first line of anti-viral defenses. The rhIFN?2b, a Type I interferon, is a naturally occurring protein integral to the body’s first line of anti-viral defenses. There is evidence that coronaviruses, such as COVID-19, have mechanisms which suppress IFN?2b production, allowing the virus to evade the innate immune system and replicate unabated. Multiple clinical analyses show a significant link between deficiency in Type 1 interferon and development of severe COVID-19 disease. There is also accumulating evidence from preclinical studies that coronavirus replication is blocked by the addition of exogenous IFN?2b, thereby allowing cells to restore their normal anti-viral activity. An exploratory study in Wuhan, China, in COVID-19 patients, showed that patients treated with inhaled rhIFN?2b had a more rapid rate of viral clearance than patients in the comparator arm who did not receive inhaled rhIFN?2b. Announcement • Jun 08
BetterLife Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.61 million. BetterLife Pharma Inc. has completed a Composite Units Offering in the amount of CAD 2.61 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 6,525,000
Price\Range: CAD 0.4
Discount Per Security: CAD 0.04 Announcement • May 29
BetterLife Pharma Inc. has completed a Composite Units Offering in the amount of CAD 5.5 million. BetterLife Pharma Inc. has completed a Composite Units Offering in the amount of CAD 5.5 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 13,750,000
Price\Range: CAD 0.4
Discount Per Security: CAD 0.032 Announcement • May 15
BetterLife Pharma Inc. announced that it has received $0.8 million in funding BetterLife Pharma Inc. (OTCPK:BETR.F) announced a non-brokered private placement of 1,142,857 common shares at a price of $0.70 per share for gross proceeds of $800,000 on May 14, 2021. The transaction included participation from one strategic investor. The common shares issued pursuant to the transaction are subject to a hold period under applicable securities laws, which hold period expires four months and a day following the date of issuance. Announcement • Mar 31
BetterLife Pharma Inc. announced that it has received CAD 3.934805 million in funding On March 29, 2021, BetterLife Pharma Inc. (OTCPK:BETR.F) closed the transaction. The company has received CAD 3,934,805 in the transaction. The company has issued 1,779,833 common shares at a price of CAD 1.40 per share for gross proceeds of CAD 2,491,766.20 in its second and final tranche. Announcement • Mar 10
BetterLife Pharma Inc. Enters Research Agreement with Carleton University for TD-0148A Depression Studies BetterLife Pharma Inc. announced it has entered into an agreement with University of Carleton University for TD-0148A’s research in preclinical models of depression. TD-0148A is a second-generation lysergic acid diethylamide (LSD) derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations. As part of the research agreement, Dr. Argel Aguilar-Valles’ team will work with BetterLife to test TD-0148A in both in vitro and in vivo models that are established in their lab. The team’s expertise is to understand the molecular mechanisms that underlie psychiatric and neurodevelopmental disorders. They use a combination of biochemistry, molecular biology, neuronal culture, and animal models to do this. Announcement • Mar 04
BetterLife Pharma Inc. Enter into an Agreement with Eurofins CDMO Alphora Inc. for Mental Disorders and Viral for TD-0148A's GMP Manufacturing BetterLife Pharma Inc. announced that it has entered into an agreement with Eurofins CDMO Alphora Inc. for mental disorders and viral for TD-0148A's GMP manufacturing. BetterLife's TD-0148A is a second-generation lysergic acid diethylamide ("LSD") derivative molecule, 2-bromo-LSD, that BetterLife believes will mimic the projected therapeutic potential of LSD without causing its undesirable psychoactive dissociative side effects, such as hallucinations. Eurofins CDMO will be conducting process development, scale-up and GMP manufacture of TD-0148A at its cGMP plant facility in Mississauga, Ontario. The manufacturing will be based on BetterLife's proprietary process that does not involve any controlled substances. Announcement • Feb 03
BetterLife Pharma Inc. Files Patent Protection on Dihydrohonokiol-B for Treatment of Anxiolytic Use Disorder BetterLife Pharma Inc. announced that it has filed patent protection on the newest compound to enter its pipeline, dihydrohonokiol-B (“TD-010”). Specifically, BetterLife has filed for patent protection for the use of TD-010 as a treatment for sedative, hypnotic, or anxiolytic use disorder. Studies by the United States Department of Veterans Affairs have recently indicated that prescription drug abuse has reached epidemic levels. In fact, benzodiazepine prescriptions spiked 34% from mid-February to mid-March of 2020, coinciding with the media's reporting on the outbreak of the novel coronavirus. Announcement • Jan 29
BetterLife Pharma Inc. Engages Eurofins Discovery for Its Next Generation Psychedelics 2-Bromo-Lsd Fda Ind-Enabling Pharmacology Studies BetterLife Pharma Inc. announced it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. FDA Investigational New Drug -enabling pharmacology studies. TD-0148A is a second-generation Lysergic Acid Diethylamide derivative molecule that BetterLife believes will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations. Eurofins Discovery will be conducting the IND-enabling in-vitro preclinical primary pharmacology and safety pharmacology studies on TD-0148A at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs. Eurofins Discovery will be conducting the IND-enabling in-vitro preclinical primary pharmacology and safety pharmacology studies on TD-0148A at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs. Announcement • Jan 28
BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases BetterLife Pharma Inc. announced it has confirmed stability of its inhalable interferon product through six months of real- time testing. The testing was conducted at -20°C and +2°C to +8°C temperatures which correspond to ordinary freezer and refrigerator temperatures. The interferon met all established stability testing criteria. The ability to ship, store and use the product at these temperatures greatly simplifies the distribution chain and patient use protocols. Announcement • Jan 20
BetterLife Pharma Inc. Confirms Non-Controlled Status of 2-Bromo-LSD with Health Canada BetterLife Pharma Inc. announced that Health Canada has confirmed that 2-bromo-LSD is not a controlled substance. According to Health Canada, "the information currently available at the Controlled Substances Directorate, 2-bromo-LSD is NOT CONTROLLED under the Schedules to the Controlled Drugs and Substances Act.". Announcement • Jan 12
BetterLife Pharma Inc. provide Clinical Update BetterLife Pharma Inc. provided an overview of the Company’s primary plans for this calendar year to develop 3 novel therapeutic products, each addressing significant unmet needs with multi-billion dollar market potential. TD-0148A (2-bromo-lysergic acid diethylamide; 2-bromo-LSD) is an orally administered non-hallucinogenic analog of LSD. BetterLife plans to develop TD-0148A for the treatment of mental disorders such as severe depression, post-traumatic stress disorder and substance dependencies. The Company’s initial clinical focus will be on treatment-resistant depression. BetterLife is planning to have a pre-IND meeting with the USFDA in Second Quarter 2021, with the goal to file an IND and initiate a Phase 1 clinical trial in healthy volunteers in this calendar year. Subject to health regulatory authorities’ approvals, the Company is also planning independent investigator studies in parallel with the IND filing to begin in first quarter and second quarter of 2021. TD-0148A’s patented process allows for cost effective manufacturing of TD-0148A, does not use LSD as a starting point nor generates LSD at any stage in the process. The Company will conduct process development, scale-up and GMP manufacturing of TD-0148A during this calendar year, leading up to the IND. The Company will also conduct the necessary IND-enabling preclinical studies in the same time frame. AP-003 is a BetterLife patent protected interferon alpha-2b (IFN-a2b) inhalation formulation. The Company is developing AP-003 for the treatment of pandemic respiratory viral infections, with the initial focus being on early stage COVID-19. AP-003 can be self-administered by the patient at home via a nebulizer. Based on guidance received from the USFDA, the Company has initiated the necessary preclinical IND-enabling studies, with the goal to file the IND by third quarter 2021. Subject to health regulatory authorities’ approvals, the Company is also considering conduct of AP-003 trials in COVID-19 patients in first quarter and second quarter of 2021 in ex-North American territories, using previously manufactured AP-003. The Company is quite advanced in its process development and scale-up of its proprietary IFN-a2b manufacturing, which it aims to complete by end of First Quarter 2021. If these studies are executed, a bridging clinical trial between the old and new manufactured AP-003 will also be conducted to enable use of the ex-North American data as supportive for the US IND. The Company hopes to be able to initiate a registration directed study in the US following the IND. Announcement • Jan 08
BetterLife Pharma Inc. Announces Formation of Next Generation Psychedelic Research Advisory Board and Appointment of Hattie Wells as Its First Member BetterLife Pharma Inc. announced the formation of its Next Generation Psychedelic Research Advisory Board and appointment of highly experienced Ms. Hattie Wells as its first member. Hattie Wells brings over 20 years of experience working with psychedelic molecules and the therapeutic benefits they confer to individuals suffering from mental health and polysubstance abuse disorders. Ms. Wells’ research has been published by MAPS (the Multidisciplinary Association for Psychedelic Studies), and she serves as Co-Director of Breaking Convention, Europe’s large conference on psychedelic consciousness. Ms. Wells has worked for a variety of NGOs including Amnesty International, Transform Drug Policy Foundation, The International Center for Ethnobotanical Education, Research, and Service (ICEERS), the Global Diversity Foundation, and The Joint Nature Conservation Committee and Centre for Biocultural Diversity. For the past four years, Ms. Wells worked as Policy Projects Coordinator and Operations Manager at the Beckley Foundation. Announcement • Jan 06
BetterLife Pharma Inc. Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD BetterLife Pharma Inc. announced it has applied for patent protection of new 2-Bromo-LSD formulations and their use in the treatment of depression and mood disorders. 2-Bromo-LSD is a nontoxic second-generation LSD-derived molecule that mimics the therapeutic potential of LSD, without the psychedelic effects or hallucinations. BetterLife’s recent acquisition of the assets of Transcend Biodynamics, makes it the only entity able to synthesize 2-Bromo-LSD utilizing a patented process which obviates the need to first synthesize LSD-25, eliminating the regulatory barriers of working with a Schedule 1 substance. Announcement • Dec 30
BetterLife Pharma Inc. Appoints Sergei Stetsenko to Board of Directors BetterLife Pharma Inc. announced that it has added Mr. Sergei Stetsenko to its Board of Directors to prepare for its growth phase in psychedelic medicines. Mr. Stetsenko is a financier and venture capitalist who is acting Chief Executive Officer of CRG Finance AG. As lead investor of CRG Finance, Mr. Stetsenko has helped acquire, build and exit businesses through public markets and raising capital for companies in the technology, healthcare, communications and natural resources sectors. He is currently the Chief Executive Officer of BlockchainK2 Corp. Announcement • Dec 24
BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team BetterLife Pharma Inc. announced that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company. Mr. Kroupa and Mr. Kirkland will join the senior management team of BetterLife as Chief Psychedelics Officer and Chief Psychedelics Scientist, respectively. Patrick Kroupa, president of Transcend Biodynamics LLC, will be joining the management team at BetterLife as Chief Psychedelic Officer. Mr. Kroupa has over 20 years experience working with a wide spectrum of psychedelic compounds to address mental health and drug dependence disorders. Patrick brings a tremendous breadth of experience utilizing cutting-edge molecular advancements to enhance the positive outcomes of unaddressed patient populations. Justin Kirkland is a chemist with experience in natural products, small molecules, peptide synthesis, analytical chemistry, and drug formulations for improved bioavailability. He was recently awarded a U.S. patent for the improved synthesis of the ergoline, 2-bromo-LSD. Announcement • Dec 22
BetterLife Pharma Inc. (OTCPK:BETR.F) completed the acquisition of Assets in Transcend Biodynamics LLC. BetterLife Pharma Inc. (OTCPK:BETR.F) signed a definitive agreement to acquire assets in Transcend Biodynamics LLC for CAD 13.1 million on December 8, 2020. Under the terms of transaction, total of 13.333333 million shares are issued. The transaction is subject to customary closing conditions, including regulatory approvals.
BetterLife Pharma Inc. (OTCPK:BETR.F) completed the acquisition of Assets in Transcend Biodynamics LLC on December 20, 2020. Is New 90 Day High Low • Dec 16
New 90-day high: CA$1.25 The company is up 32% from its price of CA$0.95 on 16 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 47% over the same period. Announcement • Dec 03
BetterLife Pharma Inc. announced that it has received CAD 2.944868 million in funding BetterLife Pharma Inc. (OTCPK:BETR.F) announced a reasonable commercial efforts private placement of 5,889,735 special warrants at a price of CAD 0.50 per warrant for gross proceeds of CAD 2,944,867.50 on December 2, 2020. Each special warrant is exercisable, for no additional consideration, into one unit, with each unit consisting of one common share and one common share purchase warrant. Each warrant will entitle the holder thereof to acquire one common share at an exercise price of CAD 0.60 per warrant share, for a period of 36 months after the closing of the transaction. All unexercised special warrants will automatically be exercised on the day that is the earlier of four months and a day following the closing, and as soon as reasonably practicable, and in any event no later than the third business day, after a receipt is issued for the final Prospectus qualifying the distribution of the Units underlying the special warrants and the units underlying the compensation options granted to the agents. Announcement • Nov 19
Betterlife Pharma Inc. Provides Clinical and Regulatory Update for Its Ap-003 Covid-19 Clinical Trials Using Inhaled Interferon Alpha 2B BetterLife Pharma Inc. announced to provided a clinical and regulatory update for its AP-003 COVID-19 clinical trials using inhaled interferon alpha 2b. While recent advancements in vaccines may seem to provide a glimmer of hope for bringing the pandemic to a close, it remains to be seen how safe and effective they will be, and for how long. The importance of life-saving COVID-19 therapeutics is as great ever, and the support for the Company’s use of interferon as a therapeutic for COVID-19 is compelling. Type I IFNs are natural first line of defence against ANY and ALL viruses. The human body has a non-specific surveillance system in all its cells, since any cell can be infected - that detects virus and immediately triggers a response in that cell. This is true whether it is a respiratory virus targeting the airways and lungs (flu and coronaviruses), a virus that targets the liver (hepatitis B or C), the heart (Coxsackie virus), the gut (many enteric viruses), the brain (Zika), or whether the virus enters the skin through a mosquito bite (dengue, West Nile virus). This IFN response is highly important as some intelligent viruses have evolved to have specific genes that block this IFN response. because viruses have co-evolved to very specifically have genes that will block this IFN response. In the high profile publication referenced above, it was shown that not only does SARS CoV-2 blunt/diminish an IFN response, thereby disabling an effective immune response to this infection, but that those individuals who become infected that have low blood levels of IFN tend to experience a more severe illness. Similarly, those individuals who have any mutations in genes associated with the IFN response also tend to have a more severe response to COVID-19. Individuals who, for whatever reason, have antibodies to IFN, will also elicit a more severe COVID. The importance of IFN response has also been reflected in the development of the Pfizer vaccine. The vaccine stimulates the production of IFN gamma in T Cells (responsible for fighting infections). IFN gamma is Type II IFN. Both Type I (the Company’s interferon alpha 2b) and type II interferons (are central to both combating virus infection and modulating the antiviral immune response. Notably, IFN targets many different stages of the virus life cycle - from blocking entry into cells, to preventing uncaring of enveloped viruses, to degrading the virus genome, to blocking the assembly of the virus particle and prevent virus form getting out of cells. When cells have a huge number of virus particles, IFN will kill the cell - and the virus. IFN will also recruit specific immune cells to a site of infection, and activate them to clear the infection. Announcement • Nov 11
BetterLife Pharma Inc. Announces a Clinical and Regulatory Update for its AP-003 COVID-19 Clinical Trials Following Discussions with the U.S Food and Drug Administration BetterLife Pharma Inc. announced a clinical and regulatory update for its AP-003 COVID-19 clinical trials following discussions with the U.S Food and Drug Administration (FDA). AP-003 is the Company's proprietary and patented inhalation-based interferon alpha 2b formula. While AP-003 will be initially investigated for efficacy against COVID-19, the Company believes AP-003 has other potential clinical targets such as prevention and prophylaxis of other viral infections, such as Ebola and those caused by other coronaviruses, which BetterLife intends to consider as supplementary development programs. Furthermore, since interferon treatment is hypothesized to work by `awakening' the immune system and circumventing the interferon resistance of SARS-CoV-2 (the virus which causes COVID-19) the Company also believes that its AP-003 treatment could be effective in potential SARS-CoV-2 mutations, such as mutations of the spike proteins. Scientific Rationale for AP-003. There have been other Interferon based treatment trials: In May of this year, Frontiers of Immunology quoted a study from Wuhan which concluded that the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 significantly accelerated clearance of the virus from the airways of patients. Moreover, not only did IFN a2b help patients' immune systems clear the coronavirus faster, it also seemed to reduce certain inflammatory proteins linked to severe COVID-19 complications. More recently, a UK trial by Synairgen PLC also caused much excitement, strongly demonstrating that treatments using an interferon beta inhalation in COVID-19 patients significantly improved their condition and sped up recovery by 79%. While both AP-003 and interferon beta are hypothesized to bypass the COVID-19 induced interferon production blockade, BetterLife believe that their proprietary inhaled alpha 2b (exclusively owned and developed by the Company) could be much more effective against the severity and duration of COVID-19 than interferon beta. Planned Clinical Study Design: The AP-003 trials is a multicenter randomized placebo-controlled trial that will enroll 150 patients with COVID-19 with mild to moderate symptoms to hasten recovery and thus prevent disease progression. Inhaled dosing allows delivery of AP-003 directly to the lung tissue most at risk from the coronavirus. The trial will be conducted in 10 sites in Australia. Patients will be randomized to receive inhaled AP-003 plus standard of care or placebo plus standard of care. The primary endpoints will be improvement in patient function over 14 days and improvement in blood oxygenation. Secondary endpoints will include clinical deterioration and hospitlaizations, changes in vital signs including blood oxygenation as measured by pulse oximetry, changes in COVID symptoms such as dyspnea, and changes in levels of cytokines. Is New 90 Day High Low • Oct 27
New 90-day low: CA$0.77 The company is down 67% from its price of CA$2.30 on 29 July 2020. The Canadian market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Announcement • Oct 10
An unknown buyer signed a share purchase agreement to acquire Pivot Pharmaceuticals Manufacturing Corp from BetterLife Pharma Inc. (OTCPK:BETR.F). An unknown buyer signed a share purchase agreement to acquire Pivot Pharmaceuticals Manufacturing Corp from BetterLife Pharma Inc. (OTCPK:BETR.F) on October 2, 2020. Under the terms, Buyer will settle Pivot and the BetterLife Pharma’s outstanding obligations with the lessor of the Facility of CAD 0.14 million (CAD 0.07 million settled as of October 8, 2020), 2) Cancellation of any amounts that the Pivot or the BetterLife Pharma may owe to the Buyer, 3) Buyer’s assumption of the lease of the Facility as of September 1, 2020, 4) Cancellation by Pivot of obligations that the Buyer owes to Pivot of CAD 0.18 million, 5) Buyer’s assumption of further obligations with respect to the Application, and 6) Buyer’s discontinuation of its lawsuit filed in the Province of Quebec against Pivot. Closing of this transaction is expected to occur imminently. Is New 90 Day High Low • Oct 09
New 90-day low: CA$0.85 The company is down 55% from its price of CA$1.90 on 10 July 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Announcement • Sep 18
BetterLife Scales up Manufacturing of AP-003 (Interferon Alpha 2b) to Prepare for Clinical Trials BetterLife Pharma Inc. announced it has entered into an agreement with List Biological Laboratories Inc. (“List Labs”) for the manufacture of its proprietary interferon alpha 2b for the treatment of COVID-19. Under the terms of the agreement, List Labs will provide manufacturing services from its biological development and cGMP manufacturing facility in Campbell, California. The Company also announces that it is not aware of any material, undisclosed corporate developments and has no material change to report at this time. Trading in the Company’s shares on the OTCQB, under the symbol “BETRF”, will resume after FINRA has reviewed recently submitted Form 211. The Company will keep the market informed as required. Announcement • Aug 12
BetterLife Pharma Inc. announced a financing transaction BetterLife Pharma Inc. (OTCPK:BETR.F) announced a private placement of units on August 11, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each warrant will entitle the holder to purchase a common share at a price of CAD 2.30 per share for a period of two years. The securities issued are subject to restriction period of four months and one day from the date of issue.
On the same day, the company has issued 716,725 units for gross proceeds of CAD 1,361,777 in its first tranche closing. 
